Clinical Trial Update: Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration? [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating whether adding pioglitazone to an SGLT2 inhibitor in adults with type 1 diabetes can further reduce HbA1c and prevent ris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)
• SGLT2 inhibitor

Snippet

Sponsor: Dasman Diabetes Institute | Conditions: Type 1 Diabetes | Phase 4 | Status: NOT_YET_RECRUITING